CTOs on the Move

Copernicus

www.cgsys.com

 
Copernicus is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cgsys.com
  • 11000 Cedar Ave Ste 145
    Cleveland, OH USA 44106
  • Phone: 216.231.0227

Executives

Name Title Contact Details

Similar Companies

Neuralink

Neuralink is developing the capabilities of the brain through technological augmentation. A "neural lace” would be surgically connected to a human brain and allow a user to interact with a computer without the bandwidth challenges that come with current input methods, including keyboards, mice and trackpads. Neuralink will explore how brain interfaces might alleviate the symptoms of dangerous and chronic medical conditions.

BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin™, a remarkable biotechnology that leverages a small sample of a patient`s own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week.

BioPharm Engineered Systems

BioPharm Engineered Systems is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZyStor Therapeutics

ZyStor Therapeutics is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Egenesis Bio

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.